Technical Analysis for BDTX - Black Diamond Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Down |
| Historical BDTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Crossed Above 20 DMA | Bullish | -4.76% | |
| Multiple of Ten Bullish | Other | -4.76% | |
| 20 DMA Resistance | Bearish | -1.26% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.26% | |
| Fell Below 20 DMA | Bearish | -1.29% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -1.29% | |
| Multiple of Ten Bearish | Other | -1.29% | |
| Outside Day | Range Expansion | -1.29% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Black Diamond Therapeutics, Inc., a biotechnology company, discover and develops small molecule, tumor-agnostic therapies for cancer treatment. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs of allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Biotechnology Cancer Enzymes Tyrosine Kinase Receptors Therapies For Cancer Epidermal Growth Factor Receptor Oncogenes Rare Genetic Diseases Kinase Erbb
Biotechnology Cancer Enzymes Tyrosine Kinase Receptors Therapies For Cancer Epidermal Growth Factor Receptor Oncogenes Rare Genetic Diseases Kinase Erbb
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 45.18 |
| 52 Week Low | 17.63 |
| Average Volume | 167,643 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 33.43 |
| 20-Day Moving Average | 39.98 |
| 10-Day Moving Average | 39.88 |
| Average True Range | 3.56 |
| ADX | 16.68 |
| +DI | 19.75 |
| -DI | 21.34 |
| Chandelier Exit (Long, 3 ATRs ) | 34.50 |
| Chandelier Exit (Short, 3 ATRs ) | 43.28 |
| Upper Bollinger Band | 44.29 |
| Lower Bollinger Band | 35.66 |
| Percent B (%b) | 0.39 |
| BandWidth | 21.59 |
| MACD Line | 1.47 |
| MACD Signal Line | 2.05 |
| MACD Histogram | -0.576 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 43.22 | ||||
| Resistance 3 (R3) | 43.48 | 42.34 | 42.53 | ||
| Resistance 2 (R2) | 42.34 | 41.28 | 42.22 | 42.29 | |
| Resistance 1 (R1) | 40.70 | 40.63 | 40.13 | 40.44 | 42.06 |
| Pivot Point | 39.56 | 39.56 | 39.28 | 39.44 | 39.56 |
| Support 1 (S1) | 37.92 | 38.50 | 37.35 | 37.66 | 36.04 |
| Support 2 (S2) | 36.78 | 37.85 | 36.66 | 35.81 | |
| Support 3 (S3) | 35.14 | 36.78 | 35.58 | ||
| Support 4 (S4) | 34.88 |
